Skip to content

Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)

To Assess the Correlation Between the Predictive Factor of Vascularity (CD74) in Malignant Pleural Mesothelioma and Treatment Results (Response Rate, and Overall Survival )

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02603315
Acronym
VITMPM
Enrollment
50
Registered
2015-11-11
Start date
2015-10-31
Completion date
2016-05-31
Last updated
2016-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Pleural Mesotheliomas

Brief summary

The purpose of this study is to To assess the correlation between the predictive factor of vascularity (CD74) in malignant pleural mesothelioma and treatment results (response rate, and overall survival) .

Detailed description

This is a randomized controlled retrospective study through Examination of paraffin blocks of the patient selected to be included in the study for assessment of the selected vascularity marker of malignant pleural mesothelioma of both types . The CD74 (LN2) antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed paraffin-embedded tissue sections using Immunohistochemistry test methods.

Interventions

OTHERmarker CD74 and vascular endothelial growth factor VEGF

correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
39 Years to 84 Years
Healthy volunteers
No

Inclusion criteria

* Histopathological confirmation of malignant pleural mesothelioma . * Full clinical data. * Availability for follow up: Personal communication will be attempted in order to collect missing information. 3-The files of all patients will be reviewed to analyze the following : * Operative data if done . * Pathological review and immunohistochemistry. * Laboratory investigations: (routine investigations: complete blood picture,liver and renal function test) * Radiological investigations:( CXR and CT-chest, Abdominal and pelvic U\\S and MRI ). * Treatment protocols applied: Radiotherapy and Chemotherapy. * Response and survival after treatment .

Exclusion criteria

* cases not receive chemotherapy ,on available of evaluation after treatment

Design outcomes

Primary

MeasureTime frameDescription
to correlate the results of the vascularity marker of pleural mesothelioma CD74 of patients attended to Ain Shams University hospitals with the result response of treatment by chemotherapy ,overall survival and progreeion free survival3-4 monthsThe cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment

Secondary

MeasureTime frameDescription
assessment of vascular enothelial growth factor (VEGF) in patient with malignant pleural mesothelioma who attended to Ain Shams University and made comparison with the result of CD 743-4 monthsThe cases diagnosed and receive at the least 2-3 cycles of chemotherapy and evaluated after treatment

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026